Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Role of Interleukin-6 in Exercise
- Conditions
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 56
- Registration Number
- NCT01073826
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
Januvia Re-examination Study (MK-0431-181)
- Conditions
- Interventions
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3483
- Registration Number
- NCT01062048
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
- Conditions
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT01046110
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey
Sitagliptin in Prevention of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- Locations
- 🇮🇳
Dr.Ambady Ramachandran, Chennai, Tamil nadu, India
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01035879
- Locations
- 🇺🇸
Impact Clinical Trials, Los Angeles, California, United States
🇺🇸dgd Research, Inc., a Cetero Research Co., San Antonio, Texas, United States
🇺🇸United Medical Associates, Binghamton, New York, United States
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- Phenomix
- Target Recruit Count
- 650
- Registration Number
- NCT00998686
- Locations
- 🇨🇿
Phenomix Investigational Site 208, Praha 10, Czech Republic
🇵🇱Phenomix Investigational Site 300, Gdansk, Poland
🇵🇱Phenomix Investigational Site 306, Pulawy, Poland
Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 20
- Registration Number
- NCT00978796
- Locations
- 🇺🇸
Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 319
- Registration Number
- NCT00976937
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840004, Medford, Oregon, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840003, Muscle Shoals, Alabama, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840006, Butte, Montana, United States
A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT00976261
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Effect of Sitagliptin on Endothelial Progenitor Cells
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2010-04-05
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 40
- Registration Number
- NCT00968006
- Locations
- 🇮🇹
University of Padova, Medical School, Padova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.